A program is described which was begun by Adria Laboratories in 1975. ADRIA-MYCINR (doxorubicin), IDAMYCINR (idarubicin) and six generic antineoplastic agents are provided to indigent patients. Entry procedures, program management and record keeping are described and the program is compared to programs offered by other pharmaceutical firms in support of indigent patients who are in need of antineoplastic drugs.
FarleyTAFlannertyJT. Late-stage diagnosis of breast cancer in women of lower socioeconomic status: Public health implication. Am J Publ Health.1989;79: 1508–1512.
2.
HowardJLundPBellG.Hospital variations in metastatic breast cancer. Med Care.1980;18: 442–455.
3.
TenenbaumL.Cancer chemotherapy: A reference guide. Philadelphia, PA: W. B. Saunders Company; 1989: 374–380.
4.
NazariNEGrahamY.ICI's patient assistance program. Drug Inf J.1990;24: 537–540.
